艾伯科技(02708.HK)徵詢債權人接受以40%支付完全及最終解決債項
艾伯科技(02708.HK)向債權人發公開信,表示過去一段時間以來一直尋求包括供股在內的不同方法融資及尋找新的投資者,以期解決債項問題,令公司重回正軌,但截至目前仍未籌措到足夠資金,主要由於近期股價波動,現有股東或潛在投資者不願意以認購價每股0.11元認購供股股份或未獲承購股份。
因此,艾伯科技徵詢債權人考慮接受以40%支付,以完全及最終解決(full and final settlement)債權人所持的債項,否則將再留待法庭判決。
針對艾伯科技的清盤呈請的下一次聆訊,將於下月29日上午9時30分舉行。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.